Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia
NCT ID: NCT01626183
Last Updated: 2016-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2012-05-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is looking into RNA in samples from younger patients with T-cell (T) acute lymphoblastic leukemia (ALL).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01653613
Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia
NCT01016379
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01520246
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01139333
Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia
NCT01119586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Characterization of the transcriptomic landscape in diagnosis and relapse of T-cell acute lymphoblastic leukemia (ALL) and the direct comparison with corresponding physiological samples (human thymus).
* Perform high-throughput transcriptome ribonucleic acid (RNA) sequencing using matched diagnostic T-precursor pediatric ALL samples (peripheral blood or bone marrow).
OUTLINE: Archived peripheral blood and bone marrow samples are analyzed for long non-coding RNA (IncRNA) expression and sequencing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
proteomic profiling
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Peripheral blood and bone marrow samples from pediatric patients with diagnosed and relapsed T-ALL
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iannis Aifantis, PhD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AALL12B8
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000735509
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-01980
Identifier Type: REGISTRY
Identifier Source: secondary_id
AALL12B8
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.